Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Ending Cash Position : ¥470 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Ending Cash Position?

Hunan Er-Kang Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥470 Mil.

Hunan Er-Kang Pharmaceutical Co's quarterly Ending Cash Position increased from Sep. 2023 (¥275 Mil) to Dec. 2023 (¥511 Mil) but then declined from Dec. 2023 (¥511 Mil) to Mar. 2024 (¥470 Mil).

Hunan Er-Kang Pharmaceutical Co's annual Ending Cash Position increased from Dec. 2021 (¥602 Mil) to Dec. 2022 (¥633 Mil) but then declined from Dec. 2022 (¥633 Mil) to Dec. 2023 (¥511 Mil).

Hunan Er-Kang Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Ending Cash Position Chart

Hunan Er-Kang Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

1,314.34

880.29

601.57

632.94

510.64

Hunan Er-Kang Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															287.24	410.35	275.15	510.64	469.74

Hunan Er-Kang Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Hunan Er-Kang Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	632.94	+	-122.302
	=	511

Hunan Er-Kang Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	510.638	+	-40.895
	=	470

Hunan Er-Kang Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Ending Cash Position

Traded in Other Exchanges

N/A

Address

Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331

Website

http://www.hnerkang.com

Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines